ALNY

Alnylam Pharmaceuticals, Inc. (ALNY) | Rumor.io

Alnylam Pharmaceuticals

ALNY

Attention (50-day avg)0%

Attention rank (50-day avg)#843

Bullish sentiment (50-day avg)59%

Price to earnings ratio44.6

Market capitalization34.2B

Earnings per share5.72

Dividend yield (TTM)—

Revenue (annual)3.7B

Net income (annual)313.7M

Social

What share of all stock conversation is about ALNY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 2

Alnylam Pharmaceuticals, Inc. ($ALNY) is considered a strong candidate for S&P 500 addition, potentially due to its GAAP profitability.
Analysts at Stifel and H.C. Wainwright have reiterated Buy ratings for $ALNY, with price targets of $318 and $455, respectively.
A large number of $ALNY put options were sold at the bid price, with 1.2 million contracts in September 290 puts.

Generated by AI

Sentiment

Of the messages about ALNY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	82.35% -17.65	58.78% +44.11	58.95% -18.07
Bearish	—	17.65% +17.65	41.22% -44.11	41.05% +18.07

Bullish· Jul 9

Analysts suggest that Alnylam Pharmaceuticals ($ALNY) is a strong buy and can increase by another 40%.
Alnylam Pharmaceuticals ($ALNY) has broken out from a long consolidation zone and is pushing toward the $380 resistance area.
Goldman Sachs predicts Alnylam Pharmaceuticals' ($ALNY) next earnings will be spectacular, with an outperform target price of $650.

Bearish· Jul 30

Alnylam Pharmaceuticals, Inc. (ALNY) cut its full-year ATTR outlook and missed quarterly sales estimates, with revenue coming in at $1.29B vs $1.32B expected.
The company's stock price plummeted 28% on the earnings miss, with some analysts attributing the decline to the market's overestimation of Alnylam's growth potential.
Alnylam's guidance cut was seen as a significant red flag, with some investors warning that the company's valuation may be unsustainable, and that it may be at risk of repeating the same downward spiral as other biotechs.

Generated by AI

Topics

Of the messages about ALNY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	60.66%	53.99%	51.01%
Analysts	0%	0%	16.29%	20.04%
Technical Analysis	0%	0%	3.51%	4.32%
Controversies	0%	36.07%	7.99%	8.85%
Macro	0%	3.28%	18.21%	14.48%
Earnings	0%	0%	0%	1.31%

Earnings· Oct 31

Alnylam Pharmaceuticals ($ALNY) reports Q3 earnings of -$1.50 EPS and $70.06M in revenue, beating estimates.
Onpattro sales reach $46M in Q3, with over 600 patients worldwide on the treatment.
Alnylam Pharmaceuticals beats EPS estimates by $0.18 and revenue estimates by $12.92M, with top-line data from Phase 1/2 clinical trials expected soon.

Analysts· Feb 24

Citigroup analyst David Lebovitz maintains Alnylam Pharmaceuticals with a Buy and lowers the price target from $270 to $265.
Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals with a Buy and maintains $240 price target.
Oppenheimer analyst Leland Gershell maintains Alnylam Pharmaceuticals with a Outperform and lowers the price target from $256 to $249.

Announcements· Oct 30

Alnylam Pharmaceuticals' Q3 2025 revenue reached $851M, a 27% increase from Q2, driven by strong sales from its TTR franchise.
The company received a subpoena from the U.S. Attorney's Office for documents related to government price reporting for AMVUTTRA, ONPATTRO, OXLUMO, and GIVLAARI, including fee and discount arrangements with distributors.
Alnylam Pharmaceuticals has raised its 2025 guidance to $3B, up from $2.7B, and reported a record profit of $251M in Q3 2025.

Controversies· Mar 17

Alnylam Pharmaceuticals ($ALNY) has filed patent infringement suits against Pfizer ($PFE) and Moderna ($MRNA) over the use of lipid nanoparticles (LNPs) in mRNA delivery.
Moderna has responded to the lawsuit, calling Alnylam's actions "blatant opportunism" and stating that Alnylam's LNPs were not suitable for mRNA delivery via injection.
The controversy surrounding the lawsuit has raised questions about Alnylam's motives, with some critics suggesting that the company's focus on social responsibility and virtue signaling is at odds with its litigation strategy.

Technical Analysis· Oct 6

$ALNY is showing signs of a potential downtrend, with a failed reject of RSI 50 on the monthly chart.
The stock's support around 40 may hold, but it needs to break 37.60 to reverse the trend.
A double bottom pattern has been observed, with the stock bouncing after reaching a low of around 30-33.

Generated by AI

Community

Of the messages about ALNY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	75%	41.67%	71.33%	56.07%
Newcomers	25%	58.33%	28.67%	43.93%

Regulars· Aug 28

The recent CARDIO-TTRansform study results, specifically the 1.14 event rate ratio from the stabilizer arm, have been met with minimal benefit expectations, but may still have an impact on Alnylam's TRITON trial.
The long-term course of approvals and commercial uptake for stabilizer therapy in the silencer study may have influenced patient baseline therapy prior to the start of the silencer study.
The full data from the CARDIO-TTRansform study may lead to a modification of Alnylam's TRITON trial, and the company's heart drug may be affected by the competing drug's surprising failure.

Newcomers· Jul 30

Newcomers are focusing on Alnylam's poor earnings report, with the company missing revenue estimates and lowering its 2026 TTR guidance.
Some investors are expressing frustration with Alnylam's leadership, questioning the decisions made by Yvonne Greenstreet and Tolga Tangular.
Others are taking a contrarian view, buying into the stock at a lower price and hoping for a rebound, with some even setting targets for a potential increase in value.

Generated by AI

News

Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. is down on ATTR-CM fears. TRITON-CM could still succeed, downside is buffered, and shares look undervalued. Click for an ALNY update.

1d agoSeeking Alpha

Also Discussed

Investors talking about ALNY also mention

#	Name	Attention
1	Ionis Pharmaceuticals, Inc.IONS	0%new
2	Arrowhead Pharmaceuticals, Inc.ARWR	0%+0
3	BridgeBio Pharma Inc.BBIO	0%-0.02
4	BioMarin Pharmaceutical IncBMRN	0%+0
5	Novartis AG Sponsored ADRNVS	0%-0.01
6	Agios Pharmaceuticals, Inc.AGIO	0%0
7	Arbutus Biopharma CorporationABUS	0%0
8	Sanofi ADRSNY	0%-0.01
9	Regeneron Pharmaceuticals, Inc.REGN	0%-0.01
10	Biogen IncBIIB	0%-0.01

Alnylam Pharmaceuticals, Inc.

Healthcare
Biotechnology

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference therapeutics. Alnylam Pharmaceuticals develops, manufactures, and commercializes medicines designed to silence disease-causing genes, with a primary emphasis on rare genetic and cardiometabolic conditions. Its current portfolio includes approved therapies for transthyretin-mediated amyloidosis, and the company also advances programs in areas such as hypertension and other genetically defined diseases. Alnylam Pharmaceuticals works across the United States, Europe, and other international markets, supporting patients through specialized treatments and healthcare partnerships. Headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals plays a significant role in the growing RNAi medicine segment, where it is recognized for translating gene-silencing science into commercial therapies for serious conditions.

Website

Location

675 West Kendall Street

Cambridge, MA, 02142

United States

Social

What share of all stock conversation is about ALNY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 2

Alnylam Pharmaceuticals, Inc. ($ALNY) is considered a strong candidate for S&P 500 addition, potentially due to its GAAP profitability.
Analysts at Stifel and H.C. Wainwright have reiterated Buy ratings for $ALNY, with price targets of $318 and $455, respectively.
A large number of $ALNY put options were sold at the bid price, with 1.2 million contracts in September 290 puts.

Generated by AI

Sentiment

Of the messages about ALNY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	82.35% -17.65	58.78% +44.11	58.95% -18.07
Bearish	—	17.65% +17.65	41.22% -44.11	41.05% +18.07

Bullish· Jul 9

Analysts suggest that Alnylam Pharmaceuticals ($ALNY) is a strong buy and can increase by another 40%.
Alnylam Pharmaceuticals ($ALNY) has broken out from a long consolidation zone and is pushing toward the $380 resistance area.
Goldman Sachs predicts Alnylam Pharmaceuticals' ($ALNY) next earnings will be spectacular, with an outperform target price of $650.

Bearish· Jul 30

Alnylam Pharmaceuticals, Inc. (ALNY) cut its full-year ATTR outlook and missed quarterly sales estimates, with revenue coming in at $1.29B vs $1.32B expected.
The company's stock price plummeted 28% on the earnings miss, with some analysts attributing the decline to the market's overestimation of Alnylam's growth potential.
Alnylam's guidance cut was seen as a significant red flag, with some investors warning that the company's valuation may be unsustainable, and that it may be at risk of repeating the same downward spiral as other biotechs.

Generated by AI

Topics

Of the messages about ALNY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	60.66%	53.99%	51.01%
Analysts	0%	0%	16.29%	20.04%
Technical Analysis	0%	0%	3.51%	4.32%
Controversies	0%	36.07%	7.99%	8.85%
Macro	0%	3.28%	18.21%	14.48%
Earnings	0%	0%	0%	1.31%

Earnings· Oct 31

Alnylam Pharmaceuticals ($ALNY) reports Q3 earnings of -$1.50 EPS and $70.06M in revenue, beating estimates.
Onpattro sales reach $46M in Q3, with over 600 patients worldwide on the treatment.
Alnylam Pharmaceuticals beats EPS estimates by $0.18 and revenue estimates by $12.92M, with top-line data from Phase 1/2 clinical trials expected soon.

Analysts· Feb 24

Citigroup analyst David Lebovitz maintains Alnylam Pharmaceuticals with a Buy and lowers the price target from $270 to $265.
Needham analyst Joseph Stringer reiterates Alnylam Pharmaceuticals with a Buy and maintains $240 price target.
Oppenheimer analyst Leland Gershell maintains Alnylam Pharmaceuticals with a Outperform and lowers the price target from $256 to $249.

Announcements· Oct 30

Alnylam Pharmaceuticals' Q3 2025 revenue reached $851M, a 27% increase from Q2, driven by strong sales from its TTR franchise.
The company received a subpoena from the U.S. Attorney's Office for documents related to government price reporting for AMVUTTRA, ONPATTRO, OXLUMO, and GIVLAARI, including fee and discount arrangements with distributors.
Alnylam Pharmaceuticals has raised its 2025 guidance to $3B, up from $2.7B, and reported a record profit of $251M in Q3 2025.

Controversies· Mar 17

Alnylam Pharmaceuticals ($ALNY) has filed patent infringement suits against Pfizer ($PFE) and Moderna ($MRNA) over the use of lipid nanoparticles (LNPs) in mRNA delivery.
Moderna has responded to the lawsuit, calling Alnylam's actions "blatant opportunism" and stating that Alnylam's LNPs were not suitable for mRNA delivery via injection.
The controversy surrounding the lawsuit has raised questions about Alnylam's motives, with some critics suggesting that the company's focus on social responsibility and virtue signaling is at odds with its litigation strategy.

Technical Analysis· Oct 6

$ALNY is showing signs of a potential downtrend, with a failed reject of RSI 50 on the monthly chart.
The stock's support around 40 may hold, but it needs to break 37.60 to reverse the trend.
A double bottom pattern has been observed, with the stock bouncing after reaching a low of around 30-33.

Generated by AI

Community

Of the messages about ALNY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	75%	41.67%	71.33%	56.07%
Newcomers	25%	58.33%	28.67%	43.93%

Regulars· Aug 28

The recent CARDIO-TTRansform study results, specifically the 1.14 event rate ratio from the stabilizer arm, have been met with minimal benefit expectations, but may still have an impact on Alnylam's TRITON trial.
The long-term course of approvals and commercial uptake for stabilizer therapy in the silencer study may have influenced patient baseline therapy prior to the start of the silencer study.
The full data from the CARDIO-TTRansform study may lead to a modification of Alnylam's TRITON trial, and the company's heart drug may be affected by the competing drug's surprising failure.

Newcomers· Jul 30

Newcomers are focusing on Alnylam's poor earnings report, with the company missing revenue estimates and lowering its 2026 TTR guidance.
Some investors are expressing frustration with Alnylam's leadership, questioning the decisions made by Yvonne Greenstreet and Tolga Tangular.
Others are taking a contrarian view, buying into the stock at a lower price and hoping for a rebound, with some even setting targets for a potential increase in value.

Generated by AI

Alnylam Pharmaceuticals

Social

Sep 2

Bullish· Jul 9

Bearish· Jul 30

Earnings· Oct 31

Analysts· Feb 24

Announcements· Oct 30

Controversies· Mar 17

Technical Analysis· Oct 6

Regulars· Aug 28

Newcomers· Jul 30

Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY)

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY)

H.C. Wainwright reiterates Alnylam stock rating on trial outlook

H.C. Wainwright reiterates Alnylam stock rating on cardiovascular trial outlook

Truist reiterates Alnylam stock rating on hypertension drug potential

Also Discussed

Alnylam Pharmaceuticals, Inc.

Company Information

Location

Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform (NASDAQ:ALNY)

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

Alnylam Needs Stronger AMVUTTRA Execution To Justify More Upside (NASDAQ:ALNY)

H.C. Wainwright reiterates Alnylam stock rating on trial outlook

H.C. Wainwright reiterates Alnylam stock rating on cardiovascular trial outlook

Truist reiterates Alnylam stock rating on hypertension drug potential

Also Discussed

Social

Sep 2

Bullish· Jul 9

Bearish· Jul 30

Earnings· Oct 31

Analysts· Feb 24

Announcements· Oct 30

Controversies· Mar 17

Technical Analysis· Oct 6

Regulars· Aug 28

Newcomers· Jul 30